US20060275503A1 - Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions - Google Patents

Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions Download PDF

Info

Publication number
US20060275503A1
US20060275503A1 US10/556,149 US55614904A US2006275503A1 US 20060275503 A1 US20060275503 A1 US 20060275503A1 US 55614904 A US55614904 A US 55614904A US 2006275503 A1 US2006275503 A1 US 2006275503A1
Authority
US
United States
Prior art keywords
acid
strontium
bone
amount
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/556,149
Other languages
English (en)
Inventor
Christian Hansen
Henrik Nilsson
Stephan Christgau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORDIC BONE AS
Osteologix AS
Original Assignee
NORDIC BONE AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORDIC BONE AS filed Critical NORDIC BONE AS
Priority to US10/556,149 priority Critical patent/US20060275503A1/en
Publication of US20060275503A1 publication Critical patent/US20060275503A1/en
Assigned to OSTEOLOGIX A/S reassignment OSTEOLOGIX A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HANSEN, CHRISTIAN, NILSSON, HENRIK, CHRISTGAU, STEPHAN
Priority to US12/434,971 priority patent/US8623422B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
US10/556,149 2003-05-07 2004-05-06 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions Abandoned US20060275503A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/556,149 US20060275503A1 (en) 2003-05-07 2004-05-06 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US12/434,971 US8623422B2 (en) 2003-05-07 2009-05-04 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200300691 2003-05-07
DKPA200300691 2003-05-07
DKPA200300931 2003-06-20
DKPA200300931 2003-06-20
US52854803P 2003-12-09 2003-12-09
DKPA200301819 2003-12-09
DKPA200301819 2003-12-09
PCT/DK2004/000327 WO2004098618A2 (en) 2003-05-07 2004-05-06 Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
US10/556,149 US20060275503A1 (en) 2003-05-07 2004-05-06 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000327 A-371-Of-International WO2004098618A2 (en) 2003-05-07 2004-05-06 Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/434,971 Continuation US8623422B2 (en) 2003-05-07 2009-05-04 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Publications (1)

Publication Number Publication Date
US20060275503A1 true US20060275503A1 (en) 2006-12-07

Family

ID=45604595

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/556,149 Abandoned US20060275503A1 (en) 2003-05-07 2004-05-06 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US12/434,971 Expired - Fee Related US8623422B2 (en) 2003-05-07 2009-05-04 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/434,971 Expired - Fee Related US8623422B2 (en) 2003-05-07 2009-05-04 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Country Status (13)

Country Link
US (2) US20060275503A1 (es)
EP (2) EP2266584B1 (es)
JP (2) JP4861817B2 (es)
AU (2) AU2004237438B2 (es)
CA (1) CA2524610C (es)
CY (2) CY1113264T1 (es)
DK (2) DK2266584T3 (es)
ES (2) ES2393781T3 (es)
HK (1) HK1152493A1 (es)
PL (2) PL1622630T3 (es)
PT (4) PT2266584E (es)
SI (2) SI1622630T1 (es)
WO (1) WO2004098618A2 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122274A1 (en) * 2003-05-07 2006-06-08 Christian Hansen Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20070282127A1 (en) * 2004-05-06 2007-12-06 Osteologix A/S High Yield And Rapid Synthesis Methods For Producing Metallo-Organic Salts
US20080026037A1 (en) * 2004-06-25 2008-01-31 Strontin Aps Compositions Comprising Strontium and Vitamin D and Uses Thereof
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
US20100143473A1 (en) * 2003-05-07 2010-06-10 Osteologix A/S Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US20110130370A1 (en) * 2009-11-27 2011-06-02 Les Laboratories Servier Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin
WO2018084959A3 (en) * 2016-09-30 2019-05-31 Nelson Deanna J Pharmaceutical quality strontium l-lactate

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123193A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
WO2006089546A1 (en) * 2005-02-28 2006-08-31 Osteologix A/S Tablets comprising a high load of strontium
ES2523796T1 (es) 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
CA2614226A1 (en) * 2005-07-06 2007-01-11 Osteologix A/S High yield synthesis methods for producing organic salts of strontium
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20080090896A1 (en) * 2006-08-28 2008-04-17 Brookler Kenneth H Strontium-Based Treatment Of Otosclerosis
DK2564839T3 (en) 2009-01-09 2016-07-25 Forward Pharma As A pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
CN102372625A (zh) * 2011-10-19 2012-03-14 山东恒通生物科技有限公司 可溶柠檬酸锶的制取方法
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
RU2512838C2 (ru) * 2012-07-24 2014-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ улучшения физического состояния организма у молодых лиц женского пола
CN109293519B (zh) * 2017-07-25 2021-09-28 北京斯利安药业有限公司 一种枸橼酸他莫昔芬晶型a的制备方法
CN110240630B (zh) * 2019-07-05 2021-08-10 浙江海洋大学 一种具有肝细胞氧化损伤保护作用的天然寡肽

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939164A (en) * 1988-06-29 1990-07-03 Adir Et Compagnie Strontium salt
US5075336A (en) * 1990-02-27 1991-12-24 Adir Et Compagnie Alkaline earth metal salts of oxa polyacid compounds
US5128364A (en) * 1991-03-28 1992-07-07 Merck Frosst Canada, Inc. Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
US5707980A (en) * 1988-08-02 1998-01-13 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
US5856356A (en) * 1996-06-17 1999-01-05 Adir Et Compagnie Use of strontium salts and pharmaceutical compositions thereof for the treatment of arthrosis
US6166078A (en) * 1996-01-23 2000-12-26 L'oreal Stable gelled composition with a high electrolyte content
US6365152B1 (en) * 2001-03-15 2002-04-02 Bovine Health Products, Inc. Scours treatment and method of making same
US20020051822A1 (en) * 2000-06-27 2002-05-02 Shire Holdings Ag Treatment of bone diseases
US20040059134A1 (en) * 2002-09-24 2004-03-25 Lucile Vaysse-Ludot Process for the industrial synthesis of tetraesters of 5-[BIS(CARBOXYMETHYL)AMINO]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates
US20040059135A1 (en) * 2002-09-24 2004-03-25 Lucile Vaysse-Ludot Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates
US20040063972A1 (en) * 2002-09-24 2004-04-01 Lucile Vaysse-Ludot Process for the industrial synthesis of strontium ranelate and its hydrates
US20050013877A1 (en) * 2001-09-28 2005-01-20 Egil Jellum Strontium compound for treatment of sub-dermal soft tissue pain
US20050142211A1 (en) * 2002-06-07 2005-06-30 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
US20060122274A1 (en) * 2003-05-07 2006-06-08 Christian Hansen Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
US20070282127A1 (en) * 2004-05-06 2007-12-06 Osteologix A/S High Yield And Rapid Synthesis Methods For Producing Metallo-Organic Salts
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB241266A (en) 1924-07-14 1925-10-14 Knoll & Co Chem Fab Improvements in the manufacture of double compounds of dimethylxanthines, earth alkali and salicylic acid
NL77097C (es) 1952-04-29
GB990957A (en) 1964-02-24 1965-05-05 Stafford Miller Ltd Strontium ion-containing toothpaste
SE340807B (es) 1966-05-06 1971-12-06 Astra Ab
US4056567A (en) 1976-03-08 1977-11-01 Lever Brothers Company Chemical processes for preparing citric acid
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3735264C1 (de) 1987-10-17 1988-08-25 Degussa Verfahren zur Herstellung von Erdalkalimetallsalzen der L-2-Pyrrolidon-5-carbonsaeure
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0381445B2 (en) * 1989-01-31 1998-01-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental composition for hypersensitive teeth
GB8906914D0 (en) 1989-03-28 1989-05-10 Beecham Group Plc Novel compositions
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2665896A1 (fr) 1990-08-16 1992-02-21 Rhone Poulenc Chimie Carboxylates metalliques, leur preparation et compositions supraconductrices obtenues a partir de ceux-ci.
HUT66379A (en) * 1991-05-28 1994-11-28 Procter & Gamble Calcium, trace mineral, vitamin d and drug therapy combinations
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
KR960705575A (ko) * 1993-10-19 1996-11-08 도나 엘. 폴락 비스포스포네이트와 성장 호르몬 분비촉진제와의 배합물(Combination of bishosphonates and growth hormone secretagogues)
CA2276945C (en) 1993-11-30 2006-08-01 G.D. Searle & Co. Tricyclic-substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions thereof
US5475021A (en) 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP1125932A3 (en) 1994-07-27 2001-08-29 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5908852A (en) 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2740341B1 (fr) 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5807873A (en) 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5756531A (en) 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5696431A (en) 1996-05-03 1997-12-09 Philips Electronics North America Corporation Inverter driving scheme for capacitive mode protection
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5750558A (en) 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5945538A (en) 1996-06-28 1999-08-31 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
ATE250576T1 (de) 1996-12-10 2003-10-15 Searle & Co Substituierte pyrrolylverbindungen zur behandlung von entzündungen
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
DE19710054A1 (de) * 1997-03-12 1998-09-17 Merck Patent Gmbh Pharmazeutische Zubereitung
ATE231504T1 (de) 1997-04-11 2003-02-15 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox- inhibitoren
US5905089A (en) 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
SE9703693D0 (sv) 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6080876A (en) 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
GB9814316D0 (en) 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
DE19837522A1 (de) 1998-08-19 2000-02-24 Clariant Gmbh Verwendung von Metall-Carboxylaten und -Sulfonaten als Ladungssteuermittel
US5980905A (en) 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6232497B1 (en) 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US20020018748A1 (en) 2000-04-03 2002-02-14 Stanley Satz Method for targeted radiotherapy, pain palliation and imaging of osteoblastic skeletal tumors and composition therefore
DE10225420A1 (de) * 2002-06-07 2003-12-24 Sanatis Gmbh Strontium-Apatit-Zement-Zubereitungen, die daraus gebildeten Zemente und die Verwendung davon
SI1622630T1 (sl) 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
WO2005123193A2 (en) 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
CA2570503A1 (en) 2004-06-17 2005-12-29 Osteologix A/S A method of improving the medical treatment of pain
CA2614226A1 (en) 2005-07-06 2007-01-11 Osteologix A/S High yield synthesis methods for producing organic salts of strontium

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939164A (en) * 1988-06-29 1990-07-03 Adir Et Compagnie Strontium salt
US5707980A (en) * 1988-08-02 1998-01-13 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5075336A (en) * 1990-02-27 1991-12-24 Adir Et Compagnie Alkaline earth metal salts of oxa polyacid compounds
US5128364A (en) * 1991-03-28 1992-07-07 Merck Frosst Canada, Inc. Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
US6166078A (en) * 1996-01-23 2000-12-26 L'oreal Stable gelled composition with a high electrolyte content
US5856356A (en) * 1996-06-17 1999-01-05 Adir Et Compagnie Use of strontium salts and pharmaceutical compositions thereof for the treatment of arthrosis
US20020051822A1 (en) * 2000-06-27 2002-05-02 Shire Holdings Ag Treatment of bone diseases
US6365152B1 (en) * 2001-03-15 2002-04-02 Bovine Health Products, Inc. Scours treatment and method of making same
US20050013877A1 (en) * 2001-09-28 2005-01-20 Egil Jellum Strontium compound for treatment of sub-dermal soft tissue pain
US20050142211A1 (en) * 2002-06-07 2005-06-30 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
US20040059134A1 (en) * 2002-09-24 2004-03-25 Lucile Vaysse-Ludot Process for the industrial synthesis of tetraesters of 5-[BIS(CARBOXYMETHYL)AMINO]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates
US20040059135A1 (en) * 2002-09-24 2004-03-25 Lucile Vaysse-Ludot Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates
US20040063972A1 (en) * 2002-09-24 2004-04-01 Lucile Vaysse-Ludot Process for the industrial synthesis of strontium ranelate and its hydrates
US20060122274A1 (en) * 2003-05-07 2006-06-08 Christian Hansen Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
US20070282127A1 (en) * 2004-05-06 2007-12-06 Osteologix A/S High Yield And Rapid Synthesis Methods For Producing Metallo-Organic Salts

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143473A1 (en) * 2003-05-07 2010-06-10 Osteologix A/S Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US8623422B2 (en) 2003-05-07 2014-01-07 Osteologix A/S Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
US20060122274A1 (en) * 2003-05-07 2006-06-08 Christian Hansen Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20100048697A1 (en) * 2003-05-07 2010-02-25 Christian Hansen Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US8609616B2 (en) 2004-02-26 2013-12-17 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
US8183409B2 (en) 2004-05-06 2012-05-22 Osteologix A/S High yield and rapid synthesis methods for producing metallo-organic salts
US20090291926A1 (en) * 2004-05-06 2009-11-26 Stephan Christgau High yield and rapid synthesis methods for producing metallo-organic salts
US20070282127A1 (en) * 2004-05-06 2007-12-06 Osteologix A/S High Yield And Rapid Synthesis Methods For Producing Metallo-Organic Salts
US20080026037A1 (en) * 2004-06-25 2008-01-31 Strontin Aps Compositions Comprising Strontium and Vitamin D and Uses Thereof
US8658206B2 (en) * 2004-06-25 2014-02-25 Mokwalo SA Compositions comprising strontium and vitamin D and uses thereof
US20110130370A1 (en) * 2009-11-27 2011-06-02 Les Laboratories Servier Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin
EA018460B1 (ru) * 2009-11-27 2013-08-30 Ле Лаборатуар Сервье Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
WO2018084959A3 (en) * 2016-09-30 2019-05-31 Nelson Deanna J Pharmaceutical quality strontium l-lactate
US10463636B2 (en) 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
US11026906B2 (en) 2016-09-30 2021-06-08 Deanna J. Nelson Pharmaceutical quality strontium L-lactate

Also Published As

Publication number Publication date
CY1113286T1 (el) 2016-04-13
EP2266584B1 (en) 2012-09-05
SI1622630T1 (sl) 2012-12-31
US20100143473A1 (en) 2010-06-10
CA2524610A1 (en) 2004-11-18
PL2266584T3 (pl) 2013-02-28
JP2006525242A (ja) 2006-11-09
SI2266584T1 (sl) 2012-12-31
AU2004237438A1 (en) 2004-11-18
ES2394782T3 (es) 2013-02-05
EP2266584A3 (en) 2011-01-26
JP2011148814A (ja) 2011-08-04
PT1745791E (pt) 2013-07-23
WO2004098618A3 (en) 2005-03-24
PT2266585E (pt) 2013-07-09
JP4861817B2 (ja) 2012-01-25
DK1622630T3 (da) 2012-12-17
EP1622630A2 (en) 2006-02-08
AU2004237438B2 (en) 2011-01-20
AU2011200693B2 (en) 2011-12-08
DK2266584T3 (da) 2013-01-02
PT1622630E (pt) 2012-10-11
CY1113264T1 (el) 2016-04-13
ES2393781T3 (es) 2012-12-28
AU2011200693A1 (en) 2011-03-10
WO2004098618A2 (en) 2004-11-18
PT2266584E (pt) 2012-12-19
US8623422B2 (en) 2014-01-07
CA2524610C (en) 2014-03-25
HK1152493A1 (en) 2012-03-02
PL1622630T3 (pl) 2013-01-31
EP1622630B1 (en) 2012-08-29
EP2266584A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
US8623422B2 (en) Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
AU2004237439B2 (en) Treating cartilage/bone conditions with water-soluble strontium salts
AU2010249227B2 (en) Controlled release composition containing a strontium salt
ES2425322T3 (es) Sales de estroncio solubles en agua para su uso en el tratamiento de afecciones del cartílago y/o de los huesos

Legal Events

Date Code Title Description
AS Assignment

Owner name: OSTEOLOGIX A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANSEN, CHRISTIAN;NILSSON, HENRIK;CHRISTGAU, STEPHAN;REEL/FRAME:021862/0549;SIGNING DATES FROM 20060320 TO 20060404

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION